Kapil Meleveedu
LightNews LightNews
banner
hematologymd.bsky.social
Kapil Meleveedu
@hematologymd.bsky.social
1.7K followers 1.3K following 33 posts
Asst Prof, Director Transplant and Cell Therapy, Malignant hematology head. Physician entrepreneur. Interested in Stem cells, myeloid and all things 🩸
Posts Replies Media Videos
hematologymd.bsky.social
Secondary malignancies after CAR-T

jamanetwork.com/journals/jam...
December 14, 2024 at 10:05 PM
hematologymd.bsky.social
Severe aplastic anemia. ASTCT guidelines 2024

www.astctjournal.org/article/S266...
December 3, 2024 at 12:17 PM
hematologymd.bsky.social
4-gene prognostic risk classifier (FLT3-ITD, KRAS, NRAS, and TP53) seems to successfully differentiate outcomes among patients with newly diagnosed AML treated with Aza/Ven than ELN 2017/2022

ashpublications.org/blood/articl...
November 22, 2024 at 6:38 PM
hematologymd.bsky.social
Ph 1 CD7 targeted CAR for R/R AML. Great CR rate (70%) in extensively treated pts. But short DoR without alloSCT. Relapse with CD7 loss

ashpublications.org/blood/articl...
November 20, 2024 at 2:48 PM
hematologymd.bsky.social
Great review on NLPHL

haematologica.org/article/down...
November 20, 2024 at 1:08 AM
hematologymd.bsky.social
Intriguing T-follicular helper (TFH) lymphomas

haematologica.org/article/view...
November 18, 2024 at 3:03 AM
hematologymd.bsky.social
Acute myelopathy following CAR-T
ashpublications.org/blood/articl...
November 17, 2024 at 6:41 PM
hematologymd.bsky.social
Snapshot @Cell
Advances in cancer immunotherapies
November 16, 2024 at 10:39 PM
hematologymd.bsky.social
From Texas to CT! Growing up fast and a great addition to our family #furrypets #cats #siamesemix
November 14, 2024 at 10:53 PM